Understand the source comparison
LL-37 Immune Protocol: Dose Comparison for Research Applications
Before implementing any dosing schedule, understand that published research uses LL-37 at widely varying concentrations depending on study design. Immune cell activation studies, antimicrobial efficacy testing, and wound healing models all use different parame
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before implementing any dosing schedule, understand that published research uses LL-37 at widely varying concentrations depending on study design. Immune cell activation studies, antimicrobial efficacy testing, and wound healing models all use different parameters.
- Innate immune activation
- 0.5–1.0 mg subcutaneous
- Every 48–72 hours
- 2–4 weeks
- Monitors cytokine production (IL-6, TNF-α) and neutrophil activity
- Antimicrobial response
- 1.0–2.0 mg subcutaneous
- Daily for acute phase, then every 48 hours
- 1–3 weeks
- Higher doses used during active infection models; taper to maintenance
- Wound healing & tissue repair
- 0.5–1.5 mg subcutaneous or topical
- Every 24–48 hours
- 2–6 weeks
- Topical application used in dermal studies; subcutaneous for systemic effects
- Chronic inflammation modulation
- Twice weekly
- 4–8 weeks
- Lower dose, longer duration; monitors CRP and inflammatory markers
- Professional Assessment
- LL-37 research protocols are highly context-dependent. Dose, frequency, and duration must align with specific study endpoints and be conducted under institutional oversight with proper controls
- Research using LL-37 for immune support protocol typically starts at 0.5mg per injection and titrates based on biomarker response. A 2021 study in Frontiers in Immunology used 1mg LL-37 every 48 hours for 14 days and measured a 35% increase in antimicrobial peptide gene expression (CAMP gene upregulation) compared to baseline. That study used subcutaneous administration in the abdominal tissue. The most common injection site due to consistent absorption rates.